Research Article
Expert Opinion on the use of Bisoprolol-Telmisartan Combination in Indian Patients with Hypertension
Manjula S*and Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
*Corresponding author: Manjula S, Department of Medical Services, Micro Labs Limited, 31 Race Course Road, Bangalore, Karnataka, India- 560001 Email Id:drmanjulas@gmail.com
Copyright: ©2024 Manjula S, et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article Information:Submission: 20/12/2023; Accepted: 16/01/2024; Published: 19/01/2024
Abstract
Background:The combination of bisoprolol and telmisartan has been recognized as a viable treatment option for hypertension management in India. However, there was a dearth of information available on the preference of antihypertensives in the actual clinical practice among clinicians.
Objective:To assess the prescription pattern of antihypertensive medications and evaluate the real-world practice of bisoprolol + telmisartan combination therapy for hypertension management in the Indian context.
Methodology: A cross-sectional, multiple-response questionnaire-based survey was conducted among clinicians with expertise in treating hypertension. The survey consisted of 25 items and focused on the prescription practices of antihypertensive medications, as well as the utilization of bisoprolol + telmisartan combination therapy for hypertension treatment. Descriptive statistics were used to analyze the data, and categorical variables were represented as percentages.
Results: The study analyzed the responses of 647 participants. It was found that 47% of the respondents followed the American Hypertension Guidelines for hypertension management. Telmisartan was the preferred choice of angiotensin receptor blocker for approximately 95% of the respondents. Among the participants, 73% favored bisoprolol as the beta-blocker of choice for newly diagnosed hypertension patients, and 57% preferred a dosage of 5 mg for patients at risk for cardiovascular disease. Furthermore, 44% of the respondents believed that 20-40% of hypertension patients required a dual antihypertensive drug combination. Nearly 70% of the participants reported improvements in organ function, specifically in target organs affected by hypertension such as the heart, kidneys, and blood vessels, when using the bisoprolol + telmisartan combination.
Conclusion: It was observed that telmisartan was the preferred choice as an angiotensin receptor blocker, while bisoprolol was favored as the beta-blocker for newly diagnosed hypertension patients. The combination of bisoprolol + telmisartan has been shown to be effective in managing hypertension, reducing cardiovascular risk, and improving organ function
Objective:To assess the prescription pattern of antihypertensive medications and evaluate the real-world practice of bisoprolol + telmisartan combination therapy for hypertension management in the Indian context.
Methodology: A cross-sectional, multiple-response questionnaire-based survey was conducted among clinicians with expertise in treating hypertension. The survey consisted of 25 items and focused on the prescription practices of antihypertensive medications, as well as the utilization of bisoprolol + telmisartan combination therapy for hypertension treatment. Descriptive statistics were used to analyze the data, and categorical variables were represented as percentages.
Results: The study analyzed the responses of 647 participants. It was found that 47% of the respondents followed the American Hypertension Guidelines for hypertension management. Telmisartan was the preferred choice of angiotensin receptor blocker for approximately 95% of the respondents. Among the participants, 73% favored bisoprolol as the beta-blocker of choice for newly diagnosed hypertension patients, and 57% preferred a dosage of 5 mg for patients at risk for cardiovascular disease. Furthermore, 44% of the respondents believed that 20-40% of hypertension patients required a dual antihypertensive drug combination. Nearly 70% of the participants reported improvements in organ function, specifically in target organs affected by hypertension such as the heart, kidneys, and blood vessels, when using the bisoprolol + telmisartan combination.
Conclusion: It was observed that telmisartan was the preferred choice as an angiotensin receptor blocker, while bisoprolol was favored as the beta-blocker for newly diagnosed hypertension patients. The combination of bisoprolol + telmisartan has been shown to be effective in managing hypertension, reducing cardiovascular risk, and improving organ function
Keywords:Bisoprolol; Telmisartan; Hypertension; Blood Pressure; Antihypertensive Treatment